Skip to content
Screener

Alumis Inc. ALMS Investing Cash Flow

Investing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$1.61B-241%
Amgen logo
AmgenAMGN
-$569M-46.3%
Immunome logo
ImmunomeIMNM
-$304.35M-374%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$14.44M-134%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$329.93M-366%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$40.68M-23.8%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.52B+693%
Enterprise value$3.49B+955%
P/S418.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010
(in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Maturities of marketable securities142,86264,000
Purchases of marketable securities(428,384)(24,535)
Purchases of property and equipment(164)(37)
Net cash (used in) provided by investing activities(285,686)39,428
Cash flows from financing activities
Proceeds from public offering of common stock, net of underwriter discounts, commissions and offering costs323,797
Proceeds from issuance of common stock upon exercise of stock options23,191
Net cash provided by financing activities346,988

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s investing cash flow?
Alumis Inc. (ALMS) reported investing cash flow of -$285.69M in Q1 2026.
How has Alumis Inc.'s investing cash flow changed year-over-year?
Alumis Inc.'s investing cash flow decreased by 824.6% year-over-year, from $39.43M to -$285.69M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Alumis Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude